

1. Record Nr.	UNINA9910464794103321
Autore	Ontaneda D.
Titolo	Multiple sclerosis : a guide to pharmacologic treatment // D. Ontaneda
Pubbl/distr/stampa	Torino, Italy : , : SEEEd, , 2013
ISBN	88-97419-48-8
Edizione	[First edition.]
Descrizione fisica	1 online resource (150 p.)
Soggetti	Multiple sclerosis - Treatment Pharmacology Electronic books.
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references.
Nota di contenuto	<p>""Title Page""; ""Colophon""; ""Table of Contents""; ""Section I. Introduction""; ""Scope""; ""New Therapies and Risks""; ""Overview of Multiple Sclerosis""; ""Basic pathogenesis""; ""Disease forms""; ""Approach to treatment""; ""Goals of treatment""; ""Challenges""; ""References""; ""Section II. Disease Modifying Agents for Multiple Sclerosis""; ""Interferon for MS""; ""Introduction""; ""Mechanism of Action""; ""Efficacy""; ""Safety and Risks""; ""Conclusions""; ""References""; ""Glatiramer acetate for MS""; ""Introduction""; ""Mechanism of Action""; ""Efficacy""; ""Safety and Risks""; ""Conclusions""; ""References""; ""Mitoxantrone for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Natalizumab for MS""; ""Introduction""; ""Mechanism of Action""; ""Efficacy""; ""Safety and Risks""; ""Conclusions""; ""References""; ""Fingolimod for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Teriflunomide for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusion""; ""References""; ""Dimethyl fumarate for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Section III. Treatment of relapses""; ""Defining Relapses""; ""Introduction""; ""Relapse symptoms""; ""MRI in MS Relapses""; ""Natural History of MS Relapses""; ""References""; ""Treatment of MS relapses"";</p>

""Introduction""; ""Corticosteroids (CS) and ACTH""; ""Plasma exchange""; ""IVIG""; ""References""; ""Section IV. Emerging therapies for multiple sclerosis""; ""Laquinimod for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""
""Safety and risks""""Conclusions""; ""References""; ""Alemtuzumab for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Daclizumab for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Ocrelizumab and Rituximab for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Author""
